Harbin Pharmaceutical Group Co., Ltd.

SHSE:600664 Stock Report

Market Cap: CN¥9.3b

Harbin Pharmaceutical Group Valuation

Is 600664 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600664 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600664 (CN¥3.69) is trading above our estimate of fair value (CN¥0.04)

Significantly Below Fair Value: 600664 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600664?

Key metric: As 600664 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600664. This is calculated by dividing 600664's market cap by their current earnings.
What is 600664's PE Ratio?
PE Ratio15.2x
EarningsCN¥613.05m
Market CapCN¥9.29b

Price to Earnings Ratio vs Peers

How does 600664's PE Ratio compare to its peers?

The above table shows the PE ratio for 600664 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average47.2x
600771 GuangYuYuan Chinese Herbal Medicine
132.8xn/aCN¥9.2b
300119 Tianjin Ringpu Bio-TechnologyLtd
19.9x18.3%CN¥8.4b
002275 Guilin Sanjin Pharmaceutical
21.3x13.7%CN¥8.7b
600557 Jiangsu Kanion PharmaceuticalLtd
15x19.0%CN¥8.1b
600664 Harbin Pharmaceutical Group
15.2xn/aCN¥9.3b

Price-To-Earnings vs Peers: 600664 is good value based on its Price-To-Earnings Ratio (15.2x) compared to the peer average (47.2x).

Price to Earnings Ratio vs Industry

How does 600664's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
600664 15.2xIndustry Avg. 29.6xNo. of Companies31PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 600664 is good value based on its Price-To-Earnings Ratio (15.2x) compared to the CN Pharmaceuticals industry average (29.6x).

Price to Earnings Ratio vs Fair Ratio

What is 600664's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600664 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 600664's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.31

7D

-1.4%

1Y

-24.4%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.59

7D

-2.4%

1Y

12.8%

Sichuan Kelun Pharmaceutical

CN¥48.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥30.51

7D

2.2%

1Y

7.6%